← Drug database

Zoledronic Acid Hospira (zoledronic acid)

Generic
Region
🇪🇺 EU
Active substance
zoledronic acid
Company
Pfizer Europe MA EEIG
Status
Withdrawn
Therapeutic area
Hypercalcemia
EU approval
Mon 19 Nov 2012
Designations
Generic
Application
EMEA/H/C/002365
ATC
M05BA08
Official record
www.ema.europa.eu

Indication

4 mg / 5 ml and 4 mg / 100 ml: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH). 5 mg / 100 ml: Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: in post-menopausal women; in men; at increased risk of fracture. Treatment of Paget's disease of the bone in adults.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Zoledronic Acid Hospira

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.